Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05283395 · ClinicalTrials.gov registry record · Phase 4
Rocklatan® Evaluation
A Phase 4 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 136
- Enrollment target
NCT05283395: Completed Phase 4 study, sponsored by Aerie Pharmaceuticals.
NCT05283395 is a Phase 4 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 136 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05283395, a Phase 4 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 136 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the IOP-lowering effect when subjects are switched from various latanoprost-based regimens to Rocklatan. Subjects will stop their IOP-lowering medical therapy regimen and dose with Rocklatan for the duration of the study (12 weeks).
Primary Outcome
IOP was measured using Goldmann applanation tonometry at the Baseline and Week 12 visits. One eye (study eye) contributed data to this analysis. A negative value indicates an improvement in IOP. No hypothesis testing was prespecified for this endpoint.
Interventions
- DRUG Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2022-03-28 |
| Est. Completion | 2023-03-22 |
| Phase | Phase 4 |
What the finished NCT05283395 record still lists
NCT05283395 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 1 intervention - of which Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution is the first listed.
NCT05283395 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05283395 about?
NCT05283395 is a clinical study titled "Rocklatan® Evaluation". The objective of this study is to evaluate the IOP-lowering effect when subjects are switched from various latanoprost-based regimens to Rocklatan. Subjects will stop their IOP-lowering medical therapy regimen and dose with Rocklatan for the duration of the study (12 weeks).
What is the current status of trial NCT05283395?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 136 participants. The study started on 2022-03-28. Estimated completion is 2023-03-22.
What interventions are being tested in trial NCT05283395?
The interventions under investigation include: Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT05283395?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05283395's enrollment target sits among peer trials
136 596th of 2000 higher than 1,400 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI